Intellia Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Intellia Therapeutics, Inc. on June 9, 2026. The filing details the voting results for three specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.
Material Changes and Voting Results
Three matters were voted upon at the Annual Meeting:
- Director Elections (Class I): Stockholders elected Muna Bhanji, R.Ph., Brian Goff, and Jesse Goodman, M.D., M.P.H., to three-year terms ending in 2029.
- Muna Bhanji: 57,065,465 votes For; 1,610,941 Against.
- Brian Goff: 46,090,644 votes For; 12,582,130 Against.
- Jesse Goodman: 43,004,221 votes For; 15,686,289 Against.
- Auditor Ratification: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Results: 87,833,534 votes For; 779,540 Against.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Results: 44,806,637 votes For; 13,821,404 Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the vote tallies.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the "Broker Non-Votes" (30,124,178) which appeared in the director and executive compensation votes but not the auditor ratification.
- Review the full Proxy Statement referenced in the filing for detailed biographies of the newly elected directors and the specific compensation metrics approved.
- Confirm the effective date of the new auditor appointment for the 2026 fiscal year.